IMAGE: These are liver cancer organoids amenable for personalized drug testing. view more
Credit: Dr. Melanie Lee, Mechanobiology Institute Science Communications Unit.
[February 8, 2018] Liver cancer is one of the top causes of cancer deaths in the world, with a dearth of approved treatments. A major challenge in developing effective drugs for liver cancer is that current preclinical tumor models do not accurately replicate features of the tumor and the tumor environment in humans, causing many potential drugs to fail in clinical testing.
To more accurately mimic these features, researchers have developed models of liver tumors called patient-derived xenografts (PDX). Although these models provide a truer picture of how effective potential cancer drugs would be in humans, they are also expensive and time-consuming to create. Growing these PDX cancer cells in culture would be more cost effective for drug screening. However, so far, attempts to culture these cells fail to reflect the 3D tumor structure and the tumor environment.
Led by Dr Eliza Fong and Dr Toh Tan Boon, an interdisciplinary team of researchers at the NUS Departments of Physiology and Biomedical Engineering, the Cancer Science Institute of Singapore, the Institute of Bioengineering and Nanotechnology, A*STAR and the
Article originally posted at